-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although HER2 blockade can significantly improve survival in human epidermal growth factor receptor 2 (HER2)-positive breast cancer , resistance to anti-HER2 therapy remains inevitable
.
TDM-1 is the standard second-line therapy
.
Although HER2 blockade can significantly improve survival in human epidermal growth factor receptor 2 (HER2)-positive breast cancer , resistance to anti-HER2 therapy remains inevitable
The study included patients with rapidly progressive HER2-positive metastatic breast cancer treated with trastuzumab in 6 hospitals in China who switched to oral lapatinib 1250 mg qd + capecitabine (1000 mg/m2 bid d1-d14 per day) or vinorelbine Bing (25 mg/m2/time, intravenous injection, d1 and d8, every 21 days as a cycle)
.
The study included patients with rapidly progressive HER2-positive metastatic breast cancer treated with trastuzumab in 6 hospitals in China who switched to oral lapatinib 1250 mg qd + capecitabine (1000 mg/m2 bid d1-d14 per day) or vinorelbine Bing (25 mg/m2/time, intravenous injection, d1 and d8, every 21 days as a cycle)
From January 5, 2015 to May 31, 2020, 159 patients were included
With a median follow-up of 33.
Among 159 evaluable patients, the RR was 29.
6% (95% CI 22.
Among 159 evaluable patients, the RR was 29.
The most common AEs were diarrhea and hand-foot syndrome, but grade 3 or higher AEs accounted for only 3.
In conclusion, the study showed that lapatinib combined with capecitabine or vinorelbine has a significant effect after the progression of HER2-positive refractory metastatic breast cancer
.
In conclusion, the study showed that lapatinib combined with capecitabine or vinorelbine has a significant effect after the progression of HER2-positive refractory metastatic breast cancer
Original source:
Fangfang Duan, Muyi Zhong, Yuyu Ma, et al.
The efcacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC -005).
BMC Cancer (2022) 22:271.
https://doi.
org/10.
1186/s12885-022-09399-2.
Fangfang Duan, Muyi Zhong, Yuyu Ma, et al.
The efcacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC -005).
BMC Cancer (2022) 22:271.
https://doi.
org/10.
1186/s12885-022-09399-2.
Leave a comment here
